PIK3R3 and cancer: Furthermore, unlike the potential mutagenic effects associated with lymphocyte-depleting chemotherapy, which may increase the risk of secondary malignant tumors, the application of CARD11-PIK3R3 demonstrates promising potential not only in mitigating T cell exhaustion but also in maintaining a favorable safety profile.